# MarÃ-a Isabel Lucena GonzÃ¡lez

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 164 papers | 9,386 citations | 43973 48 h-index | 40881 93 g-index |
| 176 all docs | 176 docs citations | 176 times ranked | 6180 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. Gastroenterology, 2005, 129, 512-521. | 0.6 | 847 |
| 2 | Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. Gastroenterology, 2005, 129, 512-521. | 0.6 | 595 |
| 3 | Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. Gastroenterology, 2011, 141, 338-347. | 0.6 | 412 |
| 4 | Drug-induced liver injury. Nature Reviews Disease Primers, 2019, 5, 58. | 18.1 | 409 |
| 5 | Drug-induced liver injury: Interactions between drug properties and host factors. Journal of Hepatology, 2015, 63, 503-514. | 1.8 | 319 |
| 6 | The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology, 2011, 54, 931-939. | 3.6 | 279 |
| 7 | Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology, 2006, 44, 1581-1588. | 3.6 | 267 |
| 8 | Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. Hepatology, 2009, 49, 2001-2009. | 3.6 | 266 |
| 9 | Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. Gastroenterology, 2014, 147, 109-118.e5. | 0.6 | 248 |
| 10 | Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology, 2001, 33, 123-130. | 3.6 | 240 |
| 11 | Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease. Cell, 2019, 177, 881-895.e17. | 13.5 | 209 |
| 12 | GlutathioneS-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology, 2008, 48, 588-596. | 3.6 | 181 |
| 13 | Association of Liver Injury From Specific Drugs, or Groups ofÂDrugs, With Polymorphisms in HLA and Other Genes in aÂGenome-Wide Association Study. Gastroenterology, 2017, 152, 1078-1089. | 0.6 | 174 |
| 14 | Causality assessment methods in drug induced liver injury: Strengths and weaknesses. Journal of Hepatology, 2011, 55, 683-691. | 1.8 | 164 |
| 15 | Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain. Hepatology, 2006, 44, 850-856. | 3.6 | 143 |
| 16 | Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBaseâ„¢. Drug Safety, 2010, 33, 503-522. | 1.4 | 142 |
| 17 | HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology, 2004, 39, 1603-1612. | 3.6 | 134 |
| 18 | Drug induced liver injury: an update. Archives of Toxicology, 2020, 94, 3381-3407. | 1.9 | 125 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. Journal of Hepatology, 2016, 65, 532-542. | 1.8 | 115 |
| 20 | Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenetics and Genomics, 2012, 22, 784-795. | 0.7 | 108 |
| 21 | Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. World Journal of Hepatology, 2014, 6, 160. | 0.8 | 105 |
| 22 | Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology, 2010, 52, 303-312. | 3.6 | 97 |
| 23 | A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. Gastroenterology, 2019, 156, 1707-1716.e2. | 0.6 | 97 |
| 24 | Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Alimentary Pharmacology and Therapeutics, 2015, 41, 116-125. | 1.9 | 95 |
| 25 | Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. International Journal of Clinical Pharmacology and Therapeutics, 2002, 40, 2-8. | 0.3 | 92 |
| 26 | Trovafloxacin-Induced Acute Hepatitis. Clinical Infectious Diseases, 2000, 30, 400-401. | 2.9 | 91 |
| 27 | Drug-induced liver injury: insights from genetic studies. Pharmacogenomics, 2009, 10, 1467-1487. | 0.6 | 90 |
| 28 | Recurrent Drug-Induced Liver Injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis. Journal of Hepatology, 2011, 55, 820-827. | 1.8 | 89 |
| 29 | Mechanisms of drug-induced liver injury. Current Opinion in Allergy and Clinical Immunology, 2014, 14, 286-292. | 1.1 | 86 |
| 30 | Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure. Gastroenterology, 2019, 157, 552-568. | 0.6 | 85 |
| 31 | Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. Clinical Gastroenterology and Hepatology, 2018, 16, 1495-1502. | 2.4 | 83 |
| 32 | HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity. PLoS ONE, 2013, 8, e68111. | 1.1 | 81 |
| 33 | Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. Lancet Diabetes and Endocrinology,the, 2016, 4, 507-516. | 5.5 | 78 |
| 34 | Hepatotoxicity Induced by Herbal and Dietary Supplements. Seminars in Liver Disease, 2014, 34, 172-193. | 1.8 | 77 |
| 35 | The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury. Nature Communications, 2017, 8, 2068. | 5.8 | 77 |
| 36 | Antidepressant-induced hepatotoxicity. Expert Opinion on Drug Safety, 2003, 2, 249-262. | 1.0 | 75 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. European Journal of Clinical Pharmacology, 2002, 58, 435-440. | 0.8 | 72 |
| 38 | Analysis of IL-10, IL-4 and TNF-Î± polymorphisms in drug-induced liver injury (DILI) and its outcome. Journal of Hepatology, 2008, 49, 107-114. | 1.8 | 72 |
| 39 | Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. Journal of Hepatology, 2021, 75, 86-97. | 1.8 | 72 |
| 40 | Causality assessment in drug-induced hepatotoxicity. Expert Opinion on Drug Safety, 2004, 3, 329-344. | 1.0 | 70 |
| 41 | Pharmacogenomics in Drug Induced Liver Injury. Current Drug Metabolism, 2009, 10, 956-970. | 0.7 | 70 |
| 42 | Mitofusin 2 as a Driver That Controls Energy Metabolism and Insulin Signaling. Antioxidants and Redox Signaling, 2015, 22, 1020-1031. | 2.5 | 69 |
| 43 | Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. International Journal of Molecular Sciences, 2016, 17, 714. | 1.8 | 69 |
| 44 | Advanced preclinical models for evaluation of drug-induced liver injury â€“ consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. Journal of Hepatology, 2021, 75, 935-959. | 1.8 | 66 |
| 45 | Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. Antioxidants, 2021, 10, 390. | 2.2 | 64 |
| 46 | The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. International Journal of Molecular Sciences, 2016, 17, 313. | 1.8 | 63 |
| 47 | Drugâ€induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. Clinical Pharmacology and Therapeutics, 2019, 106, 245-253. | 2.3 | 58 |
| 48 | Biomarkers in DILI: One More Step Forward. Frontiers in Pharmacology, 2016, 7, 267. | 1.6 | 52 |
| 49 | Shared Genetic Risk Factors Across Carbamazepineâ€induced Hypersensitivity Reactions. Clinical Pharmacology and Therapeutics, 2019, 106, 1028-1036. | 2.3 | 52 |
| 50 | A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology, 2022, 76, 18-31. | 3.6 | 52 |
| 51 | Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 817-828. | 1.5 | 48 |
| 52 | Rechallenge in drug-induced liver injury: the attractive hazard. Expert Opinion on Drug Safety, 2009, 8, 709-714. | 1.0 | 47 |
| 53 | The value of serum aspartate aminotransferase and gammaâ€glutamyl transpetidase as biomarkers in hepatotoxicity. Liver International, 2015, 35, 2474-2482. | 1.9 | 47 |
| 54 | Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. European Journal of Gastroenterology and Hepatology, 2002, 14, 887-890. | 0.8 | 45 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). British Journal of Pharmacology, 2007, 150, 808-815. | 2.7 | 44 |
| 56 | Drug-induced liver injury in older people. The Lancet Gastroenterology and Hepatology, 2020, 5, 862-874. | 3.7 | 42 |
| 57 | Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroidâ€responsive hepatitis: report of 22 cases. Liver International, 2016, 36, 302-310. | 1.9 | 39 |
| 58 | Acute liver failure after treatment with nefazodone. Digestive Diseases and Sciences, 1999, 44, 2577-2579. | 1.1 | 38 |
| 59 | Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drugâ€induced liver injury. Liver International, 2013, 33, 1378-1385. | 1.9 | 38 |
| 60 | Antibiotic-Induced Liver Toxicity: Mechanisms, Clinical Features and Causality Assessment. Current Drug Safety, 2010, 5, 212-222. | 0.3 | 34 |
| 61 | Continuous reporting of new cases in Spain supports the relationship between HerbalifeÂ® products and liver injury. Pharmacoepidemiology and Drug Safety, 2011, 20, 1080-1087. | 0.9 | 34 |
| 62 | Hepatic Damage by Natural Remedies. Seminars in Liver Disease, 2018, 38, 021-040. | 1.8 | 33 |
| 63 | Systematic review: ibuprofenâ€induced liver injury. Alimentary Pharmacology and Therapeutics, 2020, 51, 603-611. | 1.9 | 32 |
| 64 | Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatotoxicity?. Journal of Hepatology, 2015, 62, 751-752. | 1.8 | 31 |
| 65 | Drug-induced liver injury: a safety review. Expert Opinion on Drug Safety, 2018, 17, 795-804. | 1.0 | 31 |
| 66 | Genetic Risk Factors in Drugâ€Induced Liver Injury Due to Isoniazidâ€Containing Antituberculosis Drug Regimens. Clinical Pharmacology and Therapeutics, 2021, 109, 1125-1135. | 2.3 | 31 |
| 67 | Drug use for non-hepatic associated conditions in patients with liver cirrhosis. European Journal of Clinical Pharmacology, 2003, 59, 71-76. | 0.8 | 30 |
| 68 | Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions. Drug Safety, 2016, 39, 925-943. | 1.4 | 30 |
| 69 | Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. United European Gastroenterology Journal, 2019, 7, 825-837. | 1.6 | 29 |
| 70 | Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. Pharmacological Research, 2021, 164, 105404. | 3.1 | 29 |
| 71 | Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. Pharmacological Research, 2022, 182, 106348. | 3.1 | 29 |
| 72 | Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity. Digestive Diseases and Sciences, 2000, 45, 1400-1404. | 1.1 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | A morphological method for ammonia detection in liver. PLoS ONE, 2017, 12, e0173914. | 1.1 | 28 |
| 74 | Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Annals of Hepatology, 2014, 13, 231-239. | 0.6 | 27 |
| 75 | Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction. Acta Pharmaceutica Sinica B, 2021, 11, 3685-3726. | 5.7 | 27 |
| 76 | Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review. Current Drug Safety, 2007, 2, 97-112. | 0.3 | 26 |
| 77 | Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. Clinical Therapeutics, 2009, 31, 1014-1019. | 1.1 | 26 |
| 78 | Hepatotoxicity induced by coxibs: how concerned should we be?. Expert Opinion on Drug Safety, 2016, 15, 1463-1475. | 1.0 | 26 |
| 79 | Elevated levels of circulating CDH5 and FABP1 in association with human drugâ€induced liver injury. Liver International, 2017, 37, 132-140. | 1.9 | 25 |
| 80 | Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. Frontiers in Genetics, 2012, 3, 273. | 1.1 | 23 |
| 81 | Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. Journal of Hepatology, 2021, 75, 333-341. | 1.8 | 23 |
| 82 | EASL Clinical Practice Guideline: Occupational liver diseases. Journal of Hepatology, 2019, 71, 1022-1037. | 1.8 | 22 |
| 83 | Genetic risk factors in the development of idiosyncratic drug-induced liver injury. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 153-169. | 1.5 | 22 |
| 84 | Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis. Pharmacogenetics and Genomics, 2016, 26, 414-422. | 0.7 | 21 |
| 85 | When the Creation of a Consortium Provides Useful Answers: Experience of The Latin American DILI Network (LATINDILIN). Clinical Liver Disease, 2019, 13, 51-57. | 1.0 | 21 |
| 86 | Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. Clinical Gastroenterology and Hepatology, 2022, 20, e548-e563. | 2.4 | 21 |
| 87 | Norfloxacin-Induced Cholestatic Jaundice. American Journal of Gastroenterology, 1998, 93, 2309-2311. | 0.2 | 20 |
| 88 | Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. Seminars in Liver Disease, 2019, 39, 381-394. | 1.8 | 20 |
| 89 | Chronic Hepatitis C, Ibuprofen, and Liver Damage. American Journal of Gastroenterology, 2002, 97, 1854-1855. | 0.2 | 19 |
| 90 | Is the Naranjo Probability Scale Accurate Enough to Ascertain Causality in Drug-Induced Hepatotoxicity?. Annals of Pharmacotherapy, 2004, 38, 1540-1541. | 0.9 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort. PLoS ONE, 2014, 9, e94675. | 1.1 | 19 |
| 92 | Idiosyncratic drug hepatotoxicity: a 2008 update. Expert Review of Clinical Pharmacology, 2008, 1, 261-276. | 1.3 | 18 |
| 93 | Acetaminophen-Induced Liver Injury Alters the Acyl Ethanolamine-Based Anti-Inflammatory Signaling System in Liver. Frontiers in Pharmacology, 2017, 8, 705. | 1.6 | 18 |
| 94 | Sulfasalazineâ€Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus. Clinical Pharmacology and Therapeutics, 2018, 103, 843-853. | 2.3 | 18 |
| 95 | High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. Clinical Gastroenterology and Hepatology, 2018, 16, 292-294. | 2.4 | 18 |
| 96 | Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. World Journal of Gastroenterology, 2006, 12, 5244-6. | 1.4 | 18 |
| 97 | N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review. Frontiers in Pharmacology, 2022, 13, . | 1.6 | 18 |
| 98 | â€œDrug-Induced Liver Injury Clinical Consortia: a global research response for a worldwide health challengeâ€• Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 589-593. | 1.5 | 17 |
| 99 | The administration of N-acetylcysteine causes a decrease in prothrombin time in patients with paracetamol overdose but without evidence of liver impairment. European Journal of Gastroenterology and Hepatology, 2005, 17, 59-63. | 0.8 | 16 |
| 100 | Drug-Induced Autoimmune-Like Hepatitis: A Diagnostic Challenge. Digestive Diseases and Sciences, 2011, 56, 2501-2503. | 1.1 | 16 |
| 101 | Clinical Characteristics and Outcome of Drugâ€Induced Liver Injury in the Older Patients: From the Youngâ€Old to the Oldestâ€Old. Clinical Pharmacology and Therapeutics, 2021, 109, 1147-1158. | 2.3 | 16 |
| 102 | Lymphocyte Profile and Immune Checkpoint Expression in Drugâ€Induced Liver Injury: An Immunophenotyping Study. Clinical Pharmacology and Therapeutics, 2021, 110, 1604-1612. | 2.3 | 15 |
| 103 | Setting up criteria for drugâ€induced autoimmuneâ€like hepatitis through a systematic analysis of published reports. Hepatology Communications, 2022, 6, 1895-1909. | 2.0 | 15 |
| 104 | Differential hepatoprotective role of the cannabinoid CB<sub>1</sub> and CB<sub>2</sub> receptors in paracetamolâ€induced liver injury. British Journal of Pharmacology, 2020, 177, 3309-3326. | 2.7 | 13 |
| 105 | Profile of herbal and dietary supplements induced liver injury in Latin America: A systematic review of published reports. Phytotherapy Research, 2021, 35, 6-19. | 2.8 | 13 |
| 106 | Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. Current Pharmaceutical Design, 2019, 25, 3855-3871. | 0.9 | 13 |
| 107 | Genetic variations in drug-induced liver injury (DILI): resolving the puzzle. Frontiers in Genetics, 2012, 3, 253. | 1.1 | 12 |
| 108 | Trends in Qualifying Biomarkers in Drug Safety. Consensus of the 2011 Meeting of the Spanish Society of Clinical Pharmacology. Frontiers in Pharmacology, 2012, 3, 2. | 1.6 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Effect of cyclosporin a on platelet aggregation and thromboxane/prostacyclin balance in a model of extrahepatic cholestasis in the rat. Thrombosis Research, 1996, 81, 367-381. | 0.8 | 10 |
| 110 | The influence of drug properties and host factors on delayed onset of symptoms in drugâ€induced liver injury. Liver International, 2018, 39, 401-410. | 1.9 | 10 |
| 111 | Next-Generation Sequencing of PTGS Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. Frontiers in Genetics, 2019, 10, 134. | 1.1 | 10 |
| 112 | Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drugâ€Induced Liver Injury in the Spanish DILI Registry. Liver International, 2020, 41, 1523-1531. | 1.9 | 10 |
| 113 | Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. Annals of Hepatology, 2014, 13, 231-9. | 0.6 | 9 |
| 114 | Pro-Euro-Dili Registry: A Collaborative Effort to Enhance the Understanding of Dili. Journal of Hepatology, 2016, 64, S293-S294. | 1.8 | 8 |
| 115 | Syndrome of inappropriate antidiuresis in doxylamine overdose. BMJ Case Reports, 2012, 2012, bcr-2012-007428-bcr-2012-007428. | 0.2 | 7 |
| 116 | Serious liver injury induced by Nimesulide: an international collaborative study. Archives of Toxicology, 2021, 95, 1475-1487. | 1.9 | 7 |
| 117 | Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations. Genes, 2020, 11, 1275. | 1.0 | 6 |
| 118 | Characterizing Highly Cited Papers in Mass Cytometry through H-Classics. Biology, 2021, 10, 104. | 1.3 | 6 |
| 119 | 1137 THE HLA CLASS I B*1801 ALLELE INFLUENCES HEPATOCELLULAR EXPRESSION OF AMOXICILLIN-CLAVULANATE LIVER DAMAGE AND OUTCOME IN SPANISH PATIENTS. Journal of Hepatology, 2010, 52, S439. | 1.8 | 5 |
| 120 | Use of Drugs Related to the Treatment of Diabetes Mellitus and Other Cardiovascular Risk Factors in the Spanish Population. The Di@bet.es Study. Revista Espanola De Cardiologia (English Ed ), 2013, 66, 854-863. | 0.4 | 5 |
| 121 | Heterologous COVID-19 Vaccination in Spain: A Case Study of Individual Autonomy in the Real World. Value in Health, 2022, 25, 770-772. | 0.1 | 5 |
| 122 | PP022â€"Variations in drug-induced liver injury (DILI) between different prospective dili registries. Clinical Therapeutics, 2013, 35, e24. | 1.1 | 4 |
| 123 | 518 THE SPANISHâ€"LATIN AMERICAN DILI NETWORK: PRELIMINARY RESULTS FROM A COLLABORATIVE STRATEGIC INITIATIVE. Journal of Hepatology, 2013, 58, S212-S213. | 1.8 | 4 |
| 124 | The usefulness of TV medical dramas for teaching clinical pharmacology: A content analysis of House, M.D.. Educacion Medica, 2019, 20, 295-303. | 0.3 | 4 |
| 125 | Statins: Hepatic Disease and Hepatotoxicity Risk. The Open Gastroenterology Journal, 2008, 2, 18-23. | 0.1 | 4 |
| 126 | Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. Biomedicines, 2022, 10, 55. | 1.4 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Reflections on Running Training Workshops for Research Ethics Committee Members in Spain Between 2001 and 2008. Croatian Medical Journal, 2010, 51, 552-559. | 0.2 | 3 |
| 128 | Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanateâ€"Induced Liver Injury in Spanish Patients. Frontiers in Pharmacology, 2016, 7, 280. | 1.6 | 3 |
| 129 | A New Hepatoprotective Effect of Statins: Are They Always Safe for the Liver?. American Journal of Gastroenterology, 2017, 112, 384-385. | 0.2 | 3 |
| 130 | Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences. Current Hepatology Reports, 2017, 16, 286-292. | 0.4 | 3 |
| 131 | Drugâ€induced liver and skin reactions: In need of a consensus definition. Hepatology, 2017, 65, 391-391. | 3.6 | 3 |
| 132 | DRESS cases included in the Spanish and Latin-American DILI registries: clinical phenotype and outcome. Journal of Hepatology, 2018, 68, S601. | 1.8 | 3 |
| 133 | Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machineÂlearning approach. Archives of Toxicology, 2021, 95, 1793-1803. | 1.9 | 3 |
| 134 | Indacaterol-induced severe constipation and abdominal pain: is there a role for colonic Â3-adrenoceptors?. BMJ Case Reports, 2013, 2013, bcr2013009568-bcr2013009568. | 0.2 | 3 |
| 135 | Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions. Journal of Clinical Medicine, 2021, 10, 5317. | 1.0 | 3 |
| 136 | Methionine Cycle Rewiring by Targeting miR-873-5p Modulates Ammonia Metabolism to Protect the Liver from Acetaminophen. Antioxidants, 2022, 11, 897. | 2.2 | 3 |
| 137 | Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. Methods in Pharmacology and Toxicology, 2018, , 477-496. | 0.1 | 2 |
| 138 | Corrigendum to â€œAnalysis of IL-10, IL-4 and TNF-Î± polymorphisms in drug-induced liver injury (DILI) and its outcomeâ€•[J Hepatol 49 (2008) 107â€“114]. Journal of Hepatology, 2009, 50, 636. | 1.8 | 1 |
| 139 | 486 IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) IN PATIENTS WITH PRE-EXISTING LIVER DISEASE: AN ANALYSIS OF THE CASES INCLUDED IN THE SPANISH DILI REGISTRY. Journal of Hepatology, 2011, 54, S199. | 1.8 | 1 |
| 140 | Factores de riesgo y mecanismos de toxicidad hepÃ¡tica. DaÃ±o hepÃ¡tico inducido por medicamentos y tÃ³xicos (excluido el alcohol). Medicine, 2012, 11, 573-580. | 0.0 | 1 |
| 141 | Causality Assessment. , 2013, , 287-302. | | 1 |
| 142 | P1097 : Distinguishing drug induced autoimmune hepatitis from idiopatic autoimmune hepatitis. Journal of Hepatology, 2015, 62, S761. | 1.8 | 1 |
| 143 | FRI-077-Influence of drug categorization according to labelling information in the phenotypic presentation of drug-induced liver injury (DILI): An analysis in the Spanish DILI registry. Journal of Hepatology, 2019, 70, e418. | 1.8 | 1 |
| 144 | P041â€...Tandem mass tag-based quantitative proteomic profiling identifies novel putative serum biomarkers for the diagnosis of drug-induced liver injury in patients. , 2021, , . | | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Reply. Hepatology, 2022, 76, E28-E28. | 3.6 | 1 |
| 146 | Reply:. Hepatology, 2009, 49, 1777-1779. | 3.6 | 0 |
| 147 | Un caso de hepatopatÃa tÃ³xica. Medicine, 2012, 11, 624.e1-624.e4. | 0.0 | 0 |
| 148 | PP025â€”Improving hyâ€™s law definition to better predict the risk of developing acute liver failure in drug-induced liver injury (DILI). Clinical Therapeutics, 2013, 35, e25. | 1.1 | 0 |
| 149 | Reply. Gastroenterology, 2014, 147, 1442. | 0.6 | 0 |
| 150 | P310 ANABOLIC ANDROGENIC STEROIDS (AAS) ILLICIT USE IS A RAPIDLY GROWING CAUSE OF DRUG-INDUCED LIVER INJURY (DILI): A PROSPECTIVE SERIES FROM THE SPANISHâ€“LATIN-AMERICAN DILI REGISTRY. Journal of Hepatology, 2014, 60, S169. | 1.8 | 0 |
| 151 | P309 PROGNOSTIC MODEL FOR PREDICTING DRUG-INDUCED ACUTE LIVER FAILURE. Journal of Hepatology, 2014, 60, S169. | 1.8 | 0 |
| 152 | Hepatotoxicity related to Herbals and Dietary Supplements (HDS): a cause for concern. Clinical Therapeutics, 2015, 37, e123. | 1.1 | 0 |
| 153 | Metabolic risk factors affect clinical Phenotype and outcome of Hepatotoxicity (DILI). Clinical Therapeutics, 2015, 37, e126-e127. | 1.1 | 0 |
| 154 | Clinical Networks And Consortia In Drug-Induced Liver Injury (Dili): An Opportunity For Advancing Safety Science. Clinical Therapeutics, 2015, 37, e166. | 1.1 | 0 |
| 155 | Reply. Gastroenterology, 2015, 148, 452-453. | 0.6 | 0 |
| 156 | P1098 : Influence of metabolic risk factors in hepatotoxicity (DILI) phenotype and outcome. Journal of Hepatology, 2015, 62, S761-S762. | 1.8 | 0 |
| 157 | Hepatotoxicity Associated with Non-Steroidal Anti-Inflammatory Drugs. A Comparative Analysis among Ibuprofen, Diclofenac and Nimesulide fromthe Spanish and Latin-American Dili Registries. Journal of Hepatology, 2016, 64, S239-S240. | 1.8 | 0 |
| 158 | Data Mining for Possible Drug-Host Interplay in Clinical Phenotypes of Drug-Induced Liver Injury. Gastroenterology, 2017, 152, S1080-S1081. | 0.6 | 0 |
| 159 | Jnk2 is indispensable in murine and human Ibuprofen-induced acute liver failure. Journal of Hepatology, 2017, 66, S400. | 1.8 | 0 |
| 160 | Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors. , 2018, , 625-650. | | 0 |
| 161 | Reply letter to â€œEditorial: bodybuilders bewareâ€• Alimentary Pharmacology and Therapeutics, 2019, 50, 473-473. | 1.9 | 0 |
| 162 | FRI-078-Serious liver injury induced by nimesulide: An international collaboration reporting 57 cases. Journal of Hepatology, 2019, 70, e418-e419. | 1.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Data mining techniques to identify potential clinical presentation modulators in drug-induced liver injury. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-9-13. | 0.0 | 0 |
| 164 | Reply. Hepatology, 2022, 76, E73-E73. | 3.6 | 0 |